A 2026 study in mice reveals that removing a fat-breakdown enzyme from immune cells alone doesn’t cause the severe disease seen when the enzyme is completely absent, because liver cells and other tissues compensate by producing extra enzyme. According to Gram Research analysis, this finding suggests that future gene therapy for this rare genetic disease may need to target multiple cell types simultaneously rather than focusing on immune cells alone.
Scientists discovered something surprising about a rare genetic disease that causes dangerous fat buildup in the body. When they removed a specific cleanup enzyme from immune cells in mice, the disease didn’t develop as expected. Instead, they found that the enzyme was being made by liver cells and other tissues, which compensated for the missing enzyme in immune cells. This finding could change how doctors approach gene therapy for this serious condition. According to Gram Research analysis, the study reveals that the body has backup systems to handle fat breakdown that scientists didn’t fully understand before.
Key Statistics
A 2026 research article found that mice genetically lacking the LAL enzyme only in immune cells did not develop the severe fat accumulation seen in mice completely lacking the enzyme, suggesting compensatory enzyme production by other tissues.
In a 2026 study, adding enzyme-containing fluid from liver cells to immune cells from completely LAL-deficient mice effectively prevented fat accumulation inside those cells, demonstrating that the enzyme can function across different cell types.
A 2026 analysis showed that mice lacking the LAL enzyme specifically in immune cells actually gained less weight on a high-fat diet compared to normal mice, indicating the enzyme plays a role in fat storage regulation.
The Quick Take
- What they studied: Whether immune cells called macrophages are responsible for dangerous fat buildup in a rare genetic disease caused by a missing enzyme called LAL
- Who participated: Genetically modified mice designed to lack the LAL enzyme in specific cell types, tested under normal diet and high-fat diet conditions
- Key finding: Removing the LAL enzyme from immune cells alone did not cause the disease, because other cells in the body (especially liver cells) produced extra enzyme that compensated for the loss
- What it means for you: For people with this rare disease, gene therapy approaches may need to target multiple cell types rather than just immune cells to be effective. This is still experimental research in mice and doesn’t yet apply to human treatment.
The Research Details
Researchers created special mice that were missing the LAL enzyme in different cell types. Some mice lacked it only in immune cells (macrophages), while others lacked it in both immune cells and intestinal cells. They then observed what happened to these mice when fed normal food and when fed a high-fat, high-cholesterol diet. They examined tissue samples under microscopes, measured how the body handled fats, and tested whether adding enzymes from other cells could fix the problem. This approach allowed scientists to figure out which cell types are actually responsible for the disease symptoms seen in mice that completely lack the enzyme.
Understanding which cells cause disease is crucial for developing treatments. If scientists can pinpoint the exact cells responsible, they can design therapies that target only those cells. This research shows that the problem is more complicated than originally thought—multiple cell types work together to manage fat breakdown, so fixing just one cell type isn’t enough.
This is a controlled laboratory study using genetically engineered mice, which allows researchers to isolate specific variables. The findings are based on direct observation of tissues and cellular function. However, results in mice don’t always translate directly to humans, and the study doesn’t include human patients. The research was published in a peer-reviewed scientific journal, indicating it met scientific standards for publication.
What the Results Show
The most surprising result was that mice missing the LAL enzyme only in immune cells did not develop the severe fat accumulation seen in mice completely lacking the enzyme. Scientists expected the immune cells to be the main culprits, but they weren’t. Instead, the mice’s livers and other tissues continued producing the enzyme, which compensated for its absence in immune cells. When researchers added fluid from liver cells (which contained the enzyme) to immune cells from completely deficient mice, it prevented fat from building up inside those cells. This showed that the enzyme produced by liver cells could travel to immune cells and do the job there.
One positive finding was that mice lacking the enzyme in immune cells actually gained less weight when eating a high-fat diet compared to normal mice. This suggests that the enzyme in immune cells may play a role in how the body stores fat. The study also confirmed that fat absorption in the intestines and how the body releases fats into the bloodstream were not affected by removing the enzyme from immune cells alone.
Previous research showed that mice completely lacking LAL develop severe disease with massive fat accumulation in the liver and intestines, along with infiltration of immune cells filled with fat. This new study reveals that the relationship between immune cells and disease is more nuanced than previously understood. It suggests that earlier studies may have misinterpreted which cells were causing the problem, when in fact multiple cell types working together create the disease phenotype.
This research was conducted only in mice, which have different biology than humans. The study did not measure enzyme levels directly in all tissues, so scientists couldn’t quantify exactly how much enzyme was being produced by different cell types. The sample sizes for specific experiments were not detailed in the abstract. Additionally, the study focused on one specific enzyme and one disease, so findings may not apply to other genetic storage diseases.
The Bottom Line
For people with LAL deficiency (a rare condition), this research suggests that future gene therapy should consider targeting multiple cell types rather than just immune cells. Current enzyme replacement therapy may work partly because it provides the enzyme to multiple tissues simultaneously. Patients should continue working with specialists in rare metabolic diseases. Confidence level: Moderate—this is promising laboratory research but hasn’t been tested in humans yet.
This research is most relevant to people with LAL deficiency (also called Wolman disease or cholesteryl ester storage disease) and their families. It’s also important for researchers and doctors developing new treatments for rare genetic storage diseases. People without this specific genetic condition won’t be directly affected by these findings.
This is basic research that helps scientists understand disease mechanisms. It will likely take 5-10 years or more before these insights lead to new human treatments. Current treatments for LAL deficiency focus on enzyme replacement therapy, which remains the standard approach.
Frequently Asked Questions
What is LAL deficiency and why is it dangerous?
LAL deficiency is a rare genetic disease where the body can’t break down certain fats inside cells, causing dangerous fat accumulation in the liver, intestines, and immune cells. This can lead to organ damage and serious health problems if untreated.
How could this research change treatment for LAL deficiency?
The study suggests that gene therapy should target multiple cell types, not just immune cells, because the body’s fat-breakdown system involves cooperation between liver cells, immune cells, and other tissues working together.
Does this research apply to humans with LAL deficiency right now?
Not yet. This is laboratory research in mice that helps scientists understand the disease better. Current human treatments use enzyme replacement therapy, and it will take several more years of research before these findings lead to new therapies.
Why did removing the enzyme from immune cells alone not cause disease?
Other cells in the body, especially liver cells, continued producing the enzyme and it traveled to immune cells to do the job. The body has backup systems that scientists didn’t fully understand before this research.
What does this tell us about how the body handles fat breakdown?
The research shows that fat breakdown is more complex than previously thought, involving multiple cell types working together. No single cell type is entirely responsible, which explains why targeting just one cell type may not be enough for treatment.
Want to Apply This Research?
- For users with rare metabolic disorders, track weekly liver function test results and fat-related blood markers (triglycerides, cholesterol) to monitor disease progression and treatment response
- Users can log dietary fat intake and monitor how different fat levels affect their symptoms or blood work, helping identify personal triggers and optimal nutrition strategies
- Set monthly reminders for medical appointments and blood work, track symptom severity on a 1-10 scale, and maintain a food diary to correlate diet with disease markers
This research describes laboratory findings in mice and does not represent approved human treatments. LAL deficiency (Wolman disease or cholesteryl ester storage disease) is a serious rare genetic condition that requires specialized medical care. Anyone with this condition or a family history of it should work with a metabolic disease specialist. This article is for educational purposes and should not replace professional medical advice. Always consult with a qualified healthcare provider before making any decisions about diagnosis, treatment, or management of genetic diseases.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.